Nasdaq gnlx

Nov 27, 2023 · WESTLAKE VILLAGE, Calif., Nov.

Follow. WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of ...WebGenelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer. The company is currently ...U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Tuesday. Here are some big stocks recording gains in today’s session. Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA ...

Did you know?

So far, 2023 has been a great year for Genelux Corporation (NASDAQ: GNLX), which has seen positive results from trials of its lead therapy Olvi-Vec (olvimulogene nanivacirepvec) that's primarily been active in studies pertaining to ovarian cancer. However, Genelux has also been forthcoming about its V2ACT Immunotherapy, which incorporates …In terms of stock performance, immunotherapy developer Genelux (NASDAQ:GNLX) has been the hands-down winner, with shares up an impressive 417% from their IPO price as of Monday's close.WebWESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...Market Activity. Market Activity->. Stocks; Options; Funds + ETFs; Indexes; Commodities; CryptocurrencyWESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...WebHC Wainwright started coverage of Genelux ( NASDAQ: GNLX) with a buy rating, stating that it believed the company’s lead oncolytic virus Olvi-Vec is “underappreciated” and could lead to a ...Aug 28, 2023 · WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ... Genelux Corporation (NASDAQ:GNLX) fell 8.7% to $10.83. Chegg, Inc. (NYSE:CHGG) shares declined 8.2% to $9.60. Morgan Stanley downgraded Chegg from Equal-Weight to Underweight and lowered the price ...Nasdaq provides NLS Volume, Previous Close, Today's High & Low, and the 52 week High & Low. The intraday chart, the last-five real-time quotes and sales data. Real-time stock …WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...GNLX GNLX Genelux Corp NASDAQ 20.01 -0.03 -0.15% After Hours: 20.01 0 0.00% 16:01 10/19 EDT OPEN 20.00 PREV CLOSE 20.04 HIGH 20.40 LOW 20.00 VOLUME 101.28K …WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the ...Find the latest Financials data for Genelux Corporation Common Stock (GNLX) at Nasdaq.com.WebWESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux CoIPO preview: IPOs that could start trading next wee Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. What happenedShares of Genelux (NASDAQ: GNLX) were up 14.8% for Nov 23, 2023 · Nelly Dodson. November 23, 2023. Business. Genelux Corp (NASDAQ:GNLX)’s traded shares stood at 76372.0 during the last session. At the close of trading, the stock’s price was $11.19, to imply an increase of 7.80% or $0.81 in intraday trading. The GNLX share’s 52-week high remains $40.98, putting it -266.22% down since that peak but still ... CIPhotos. Genelux ( NASDAQ: GNLX) is an immuno-oncolog

Oct 13, 2023 · Price Target. $25.00. Profile Analyst Ratings Chart Competitors Earnings Financials Insider Trades Institutional Ownership Headlines SEC Filings Short Interest Social Media. Current. Insider Ownership. Percentage. 11.70%. Number Of. WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 ...WebNasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ... Top 25 Mutual Funds Where Should I Retire? Top 25 ETFs MarketWatch Picks Close Search Overlay $749.20K Ex-Dividend Date % of Float Shorted Oct. 27, 2023 at 1:30 …Genelux press release (NASDAQ:GNLX): Q3 GAAP EPS of -$0.20 misses by $0.02. $29.9 million in cash and equivalents. Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage ...

Genelux Corp (NASDAQ:GNLX). 11.68. Delayed Data. As of Nov 29. +1.24 / +11.85%. Today's Change. 5.35. Today|||52-Week Range. 40.98. --. Year-to-Date. QuoteNASDAQ does not use this value to determine compliance with the listing requirements. Inpixon Common Stock (INPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global ...Web…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Fintel reports that on November 27, 2023, HC Wainwright &am. Possible cause: Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57.

Genelux Corporation (NASDAQ:GNLX) rose 18.4% to $23.99. Shengfeng Development Limited (NASDAQ:SFWL) gained 17.2% to $6.09. Dunxin Financial Holdings Limited (NYSE:DXF) climbed 16.8% to $1.73.Genelux Corp (NASDAQ:GNLX) 14.07 Delayed Data As of 3:59pm ET -0.37 / -2.56% Today’s Change 5.35 Today ||| 52-Week Range 40.98 -- Year-to-Date Quote Profile News Charts Forecasts Financials...WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the ...

WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as ...On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp ( NASDAQ:GNLX ). This move comes amidst a year where the insider has sold a total of 89,893 shares and …

Back to GNLX Overview. Institutional Holdings info Genelux Corporation 10% owner discloses sale of 49,987 shares (NASDAQ:GNLX). From Seeking Alpha Oct 26, 2023. Genelux Corporation (GNLX) 10% owner, Aladar ...28. 7. 2023 ... The stock is down more than 6% so far this year. Expand. NASDAQ: GNLX. Genelux. Today's Change. (11.86%) $1.24. Current Price. $11.70. YTD 1w 1m. So far, 2023 has been a great year for Genelux Corporation lowest stock price was $5.35 and its highest was Nov 29, 2023 · GNLX is trading at a 48% discount. Price $11.68. Nov 29, 2023. Fair Value $23.17. Nov 29, 2023 ... Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third ... After-Hours Trades ... Investors may trad Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have ...Back to GNLX Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ... add_box. WESTLAKE VILLAGE, Calif., May 15, 2023 (Webull offers Genelux Corp stock information, incWESTLAKE VILLAGE, Calif., June 12, 2023 ( Find the latest news headlines from Genelux Corporation Common Stock (GNLX) at Nasdaq.com. GNLX Genelux Corporation Form 4 - Statement of changes Genelux is a publicly-traded biopharmaceutical company (Nasdaq: GNLX). It currently is conducting a Phase 3 registrational trial in resistant/refractory ...Nov 27, 2023 · Fintel reports that on November 27, 2023, HC Wainwright & Co. initiated coverage of Genelux (NASDAQ:GNLX) with a Buy recommendation. Analyst Price Forecast Suggests 230.81% Upside As of November 1 ... On June 16, 2023, the NASDAQ:GNLX stock opened at $34.06, represen[WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (G0. Barclays PLC, a global financial services firm, recen WESTLAKE VILLAGE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted ...Web